Clinical trials
Infections trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 4 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 31 |
| Active, not recruiting | 1 |
| No longer available | 1 |
| Recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| ViiV Healthcare | 16 |
| St. Petersburg Research Institute of Vaccines and Sera | 3 |
| European Society for Blood and Marrow Transplantation | 2 |
| Abbott | 1 |
| Aridis Pharmaceuticals, Inc. | 1 |
| AstraZeneca | 1 |
| Bayer | 1 |
| Efferon JSC | 1 |
| Forest Laboratories | 1 |
| GlaxoSmithKline | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Infections | 35 |
| Acquired Immunodeficiency Syndrome | 14 |
| HIV Infections | 12 |
| Influenza, Human | 3 |
| Bacterial Infections | 2 |
| Cellulitis | 2 |
| Pneumonia | 2 |
| Skin Diseases, Bacterial | 2 |
| Abscess | 1 |
| Arthralgia | 1 |
Trials
Showing 76 to 35 of 35. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.